EP3589661
Viðbótarmeðhöndlun á HER2-jákvæðu brjóstakrabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
28.2.2018EP published:
1.11.2023EP application number:
18712044.9
EP translation filed:
15.1.2024Grant published:
15.2.2024EPO information:
European Patent Register
Max expiry date:
27.2.2038Expiry date:
27.2.2027Next due date:
28.2.2027
Title in English:
ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCERLanguage of the patent:
English
Timeline
Today
28.2.2018EP application
1.11.2023EP Publication
15.1.2024Translation submitted
15.2.2024Registration published
27.2.2027Expires
Owner
Name:
Genentech, Inc.Address:
1 DNA Way, South San Francisco, CA 94080, US
Name:
F. Hoffmann-La Roche AGAddress:
Grenzacherstrasse 124, 4070 Basel, CH
Inventor
Name:
BENYUNES, Mark, C.Address:
South San Francisco, CA 94080, US
Name:
ROSS, Graham, AlexanderAddress:
Welwyn Garden City Hertfordshire AL8 7PA, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762466239 PDate:
2.3.2017Country:
US
Number:
201762469317 PDate:
9.3.2017Country:
US
Number:
201762486876 PDate:
18.4.2017Country:
US
Classification
Categories:
C07K 16/32, A61P 35/00, A61K 9/00, A61K 45/06, A61K 39/395, A61K 39/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 29.1.2024
Expires: 27.2.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 29.1.2025
Expires: 27.2.2026
Payer: Árnason Faktor ehf.
Number: 9
Paid: 16.2.2026
Expires: 27.2.2027
Payer: Árnason Faktor ehf.